Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The New Economy and its Winners -- Ignore unavailable to you. Want to Upgrade?

To: Bill Harmond who wrote (7141)	5/24/2001 1:36:51 PM
From: Libbyt	Read Replies (1) \| Respond to of 57684

Genome... This is another company that is hard to decide on a "fair value" for the share price. Compared to CRA and some of the other companies dealing with genetic research, GENE seems to be an overlooked company. I owned GENE when quite a few on the AMZN board held CRA (18 months ago?), but later sold that position. I just bought a new position in GENE. Their stem cell research seems to offer some promise that will lead to the development of specific drugs by the various pharmaceutical companies.